kabutan

EIKEN CHEMICAL CO.,LTD.(4549) Summary

4549
TSE Prime
EIKEN CHEMICAL CO.,LTD.
3,105
JPY
+15
(+0.49%)
Apr 28, 3:30 pm JST
19.50
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
27.1
PBR
2.34
Yield
1.87%
Margin Trading Ratio
2.65
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
3,100 JPY 19.45 USD
Previous Close Apr 27
3,090 JPY 19.38 USD
High Apr 28, 9:00 am
3,110 JPY 19.55 USD
Low Apr 28, 9:26 am
3,075 JPY 19.29 USD
Volume
133,700
Trading Value
0.41B JPY 2.60M USD
VWAP
3098.77 JPY 19.46 USD
Minimum Trading Value
310,500 JPY 1,950 USD
Market Cap
0.11T JPY 0.67B USD
Number of Trades
292
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
409
1-Year High Feb 24, 2026
2,050
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 162,800 332,000 2.04
Apr 17, 2026 146,200 267,600 1.83
Apr 10, 2026 138,200 226,200 1.64
Apr 3, 2026 146,200 235,900 1.61
Mar 27, 2026 154,100 300,100 1.95
Company Profile
EIKEN CHEMICAL CO.,LTD. is a leading manufacturer of clinical diagnostic reagents, with a high market share in fecal occult blood test reagents. The company also produces reagents for microbiology, genetic testing, and urinalysis.
Sector
Pharmaceuticals
EIKEN CHEMICAL CO.,LTD. specializes in the manufacture and sale of clinical diagnostic reagents as its core business. The company holds the top domestic market share in fecal occult blood test reagents. It operates both domestically and internationally, with a consolidated subsidiary in China called Eiken China Co., Ltd. This Chinese subsidiary engages in contract manufacturing of the company's diagnostic reagents and the purchase, manufacture, and sale of diagnostic products. The group as a whole focuses on the diagnostic reagent business, maintaining a strong position in the domestic market while expanding overseas. International sales account for approximately one-quarter of the company's total revenue. EIKEN CHEMICAL CO.,LTD. contributes to improving the quality of healthcare by leveraging its technological expertise and product development capabilities in the field of clinical diagnostic reagents.